Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Moving Headquarters to Texas

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today said that is moving its headquarters from Fremont, Calif., to Austin, Texas.

The molecular diagnostics firm, which emerged from bankruptcy protection earlier this year, said that it will continue to perform R&D, regulatory, and quality operations at its facilities in California. All other functions will be conducted in Austin, where the firm has signed a two-year lease on its new principal place of business.

"This move allows us to take advantage of Austin's strong talent pool and cost-effective environment," Vermillion CEO and Chair of the Board of Directors Gail Page said in a statement. "Austin's central location also facilitates more efficient and effective interaction with our national sales force and our strategic partners on the East Coast, such as Quest Diagnostics and Johns Hopkins University, as well as our colleagues on the West Coast, such as PrecisionMed and Stanford University."

Vermillion expects to complete the move in September 2010.

In early trade on the Nasdaq, Vermillion's shares were unchanged at $10.74.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.